Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
16.84
+0.42 (2.56%)
Apr 8, 2026, 11:35 AM EDT - Market open
Pharming Group Revenue
In the year 2025, Pharming Group had annual revenue of $376.13M with 26.56% growth. Pharming Group had revenue of $106.50M in the quarter ending December 31, 2025, with 14.89% growth.
Revenue (ttm)
$376.09M
Revenue Growth
+26.53%
P/S Ratio
3.05
Revenue / Employee
$924,162
Employees
407
Market Cap
1.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.13M | 78.93M | 26.56% |
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
| Dec 31, 2019 | 189.39M | 34.10M | 21.96% |
| Dec 31, 2018 | 155.29M | 47.75M | 44.40% |
| Dec 31, 2017 | 107.54M | 90.83M | 543.88% |
| Dec 31, 2016 | 16.70M | 4.94M | 42.05% |
| Dec 31, 2015 | 11.76M | -13.88M | -54.13% |
| Dec 31, 2014 | 25.63M | 16.22M | 172.36% |
| Dec 31, 2013 | 9.41M | -4.59M | -32.77% |
| Dec 31, 2012 | 14.00M | 10.12M | 260.60% |
| Dec 31, 2011 | 3.88M | 3.12M | 406.76% |
| Dec 31, 2010 | 766.09K | 285.75K | 59.49% |
| Dec 31, 2009 | 480.35K | -445.02K | -48.09% |
| Dec 31, 2008 | 925.37K | -83.22K | -8.25% |
| Dec 31, 2007 | 1.01M | 815.16K | 421.44% |
| Dec 31, 2006 | 193.42K | -285.11K | -59.58% |
| Dec 31, 2005 | 478.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.12B |
| Xeris Biopharma Holdings | 291.85M |
| Geron | 183.88M |
| Septerna | 45.95M |
| EyePoint | 31.37M |
| uniQure | 16.10M |
| Inventiva | 9.31M |
| DBV Technologies | 5.64M |
PHAR News
- 1 day ago - Pharming Group to participate in April investor conferences - GlobeNewsWire
- 6 days ago - Pharming Group announces the filing of its 2025 Annual Report and Form 20-F - GlobeNewsWire
- 12 days ago - Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older - GlobeNewsWire
- 15 days ago - Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older - GlobeNewsWire
- 27 days ago - Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow - GlobeNewsWire
- 5 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - GlobeNewsWire
- 5 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - PRNewsWire
- 5 weeks ago - Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 - GlobeNewsWire